Blog

  • MedPal AI acquires eMARx to strengthen digital healthcare platform for care homes

    MedPal AI acquires eMARx to strengthen digital healthcare platform for care homes

    MedPal AI plc (LSE:MPAL) has acquired Solid State Technologies Ltd, which trades as eMARx, in a transaction valuing the business at approximately £0.47 million. eMARx provides electronic medication administration record software to UK care homes and pharmacies, and the acquisition adds a recurring, high-margin software business with an established customer base that includes both national care providers and independent operators. The existing eMARx management team will also become long-term shareholders in MedPal AI as part of the transaction.

    The acquisition completes the final software component of MedPal’s integrated Health OS platform, linking NHS prescriptions, automated dispensing from the company’s Sarus Court pharmacy hub, medication delivery and barcode-verified administration within care homes. MedPal plans to offer the eMARx platform at little or no cost to care homes that use its pharmacy services exclusively, a strategy designed to accelerate customer adoption, increase pharmacy revenues and improve medication management, safety and oversight for residents, healthcare providers and the NHS across the UK’s £27 billion care home sector.

    More about MedPal AI

    MedPal AI plc is a UK-based digital healthcare and pharmacy technology company focused on improving medication management across the care home and primary care markets. Its operations include NHS distance-selling pharmacy services, business-to-business pharmacy supply for care homes, a private healthcare clinic and Juno, its AI-powered health assistant.

    The company also operates the Sarus Court robotic dispensing hub in Runcorn, which uses BD Rowa automation technology to provide high-volume pharmacy dispensing. By integrating software, pharmacy services and artificial intelligence into a single healthcare platform, MedPal AI aims to streamline the medicines supply chain and strengthen its position in the growing UK care home market.

  • Helix Exploration launches commercial helium sales from Montana’s Rudyard project

    Helix Exploration launches commercial helium sales from Montana’s Rudyard project

    Helix Exploration PLC (LSE:HEX) has achieved a significant operational milestone by commencing commercial helium sales from its Rudyard facility in Montana. The company has loaded and dispatched its first high-pressure jumbo tube trailer containing approximately 160 Mcf of high-grade helium to an industrial gases customer, marking Helix’s first commercial sale and its transition into a revenue-generating producer just over two years after its IPO. The company expects a combination of customer-owned and company-owned trailers to support regular deliveries going forward.

    Under a spot sales agreement running until late August, Helix’s industrial gases partner has agreed to purchase all current production from the company’s three producing wells. At the same time, Helix is progressing negotiations on longer-term offtake agreements that are expected to be supported by its Keyes helium liquefaction plant. Additional production growth is anticipated as further wells receive regulatory approval and the Inez-1 well re-entry returns to service following weather-related delays. The company is expanding output into a global helium market where limited supply and strong demand from technology, healthcare and industrial sectors continue to support favourable pricing.

    Helix’s strategy is to build a fully integrated helium business by combining production at the Rudyard Project with processing capabilities at the Keyes Helium Complex. This approach is designed to capture value across the entire supply chain, from gas production through to premium liquid helium sales. Management believes growing demand for reliable domestic helium supplies in the United States creates an opportunity for Helix to establish itself as a leading independent producer and processor while also providing liquefaction services for third-party helium volumes.

    Despite reaching the important milestone of generating its first commercial revenue, the company continues to face financial challenges associated with its growth phase, including previous operating losses and negative cash flow. Technical indicators also remain weak, although Helix benefits from a debt-free balance sheet as it continues to expand production and develop its integrated helium business.

    More about Helix Exploration

    Helix Exploration PLC is a helium exploration, production and processing company listed on the London Stock Exchange. Its flagship Rudyard Project in Montana is the state’s first producing helium field and is supported by existing infrastructure and plans for further production growth.

    The company also owns the Keyes Helium Complex in Oklahoma, one of only a handful of operational helium liquefaction facilities in the United States. By combining upstream production with downstream liquefaction, Helix aims to create a vertically integrated business capable of supplying both gaseous and liquid helium to customers across North America.

  • Advanced Medical Solutions reports higher first-half revenue and maintains full-year EBITDA outlook

    Advanced Medical Solutions reports higher first-half revenue and maintains full-year EBITDA outlook

    Advanced Medical Solutions (LSE:AMS) expects to report first-half 2026 revenue of approximately £115.2 million, compared with £110.8 million in the same period last year. The increase comes despite some customer orders being delayed into July and temporary de-stocking associated with the company’s strategy to expand its direct sales operations across Europe. The performance also follows a strong comparative period for the Advanced Closure division. Despite these factors, the board remains confident that full-year EBITDA will meet current market expectations.

    The company said integration of the Peters Surgical and Syntacoll acquisitions is continuing as planned, supporting its strategy of expanding its portfolio of surgical products while delivering operational and commercial synergies. Management believes the enlarged product offering and healthy pipeline of growth opportunities position the business to deliver scalable expansion, improved margins and long-term value creation.

    Advanced Medical Solutions has shown improving revenue and cash flow in recent trading, although profitability remains below previous peak levels and leverage has increased following recent acquisitions. Technical indicators remain positive, reflecting a strong share price trend, although momentum appears stretched. Valuation remains relatively demanding, with a high price-to-earnings ratio and a modest dividend yield.

    More about Advanced Medical Solutions

    Advanced Medical Solutions Group plc is a UK-based medical technology company that develops and manufactures products for tissue healing, surgical procedures and advanced wound care. Its portfolio includes surgical adhesives, sealants, sutures and biosurgical products used by healthcare professionals around the world.

    The company is expanding its international presence through acquisitions and investment in direct sales capabilities, particularly following the acquisition of Peters Surgical. By combining advanced biomaterial technologies with an expanding commercial platform, Advanced Medical Solutions aims to strengthen its position in the global surgical and wound care markets.

  • Alternative Income REIT favours AEW UK REIT proposal over Glenstone offer

    Alternative Income REIT favours AEW UK REIT proposal over Glenstone offer

    Alternative Income REIT plc (LSE:AIRE) has confirmed it has received a possible all-share approach from AEW UK REIT plc that the board believes could offer greater value than the existing bid from Glenstone REIT plc. Under the indicative proposal, Alternative Income REIT shareholders would receive 0.725 AEW UK REIT shares for each AIRE share held, implying a value of approximately 77.4 pence per share and representing a premium to Glenstone’s current cash offer.

    The board said it considers the potential proposal from AEW UK REIT to be more attractive in terms of both valuation and governance arrangements. Discussions with AEW UK REIT are continuing as the parties work towards a possible firm offer. In the meantime, shareholders are being advised to reject Glenstone’s offer or withdraw any existing acceptances while no formal proposal has yet been announced and the takeover process under the UK Takeover Code remains ongoing.

    Alternative Income REIT continues to benefit from solid operating performance, supported by improved cash generation, a resilient property portfolio and refinancing progress. The company’s valuation also remains attractive, with a relatively low price-to-earnings ratio and a strong dividend yield. Positive share price momentum and recent corporate activity have further strengthened investor sentiment.

    More about Alternative Income REIT

    Alternative Income REIT plc is a UK-listed real estate investment trust focused on generating sustainable income from a diversified portfolio of commercial property assets. The company seeks to provide shareholders with long-term rental income through carefully selected investments supported by strong tenant covenants.

    Its strategy centres on maintaining a resilient property portfolio, preserving capital value and delivering attractive shareholder returns through income generation. The company continues to manage its portfolio actively while pursuing opportunities to enhance long-term value for investors.

  • GSK submits application to expand Bexsero booster use in Europe

    GSK submits application to expand Bexsero booster use in Europe

    GSK (LSE:GSK) has announced that the European Medicines Agency has accepted its application to update the prescribing information for Bexsero, seeking approval for a single booster dose for people aged 10 years and older who received the meningococcal B vaccine during infancy. The proposed label expansion is intended to extend protection into adolescence and early adulthood, when cases of invasive meningococcal disease experience a second peak.

    The submission is supported by data from a Phase 3b clinical trial demonstrating that a single booster dose successfully restores protective immune responses in individuals aged between 10 and 20 who completed the original vaccination schedule as infants. If the application is approved and adopted by countries with existing meningococcal B immunisation programmes, the booster could help reduce the incidence of invasive meningococcal disease while strengthening GSK’s position in the global vaccine market.

    GSK continues to benefit from strong underlying financial performance, supported by healthy operating margins, improving earnings and an attractive valuation, including a relatively low price-to-earnings ratio and a dividend yield of around 3.47%. However, these strengths are partly offset by weaker technical indicators, with the shares trading below key moving averages, as well as financial considerations including leverage and variable free cash flow generation.

    More about GSK

    GSK is a global biopharmaceutical company focused on developing innovative vaccines and medicines to prevent and treat disease. The company combines scientific research, advanced technology and global manufacturing capabilities to address a broad range of infectious diseases and chronic health conditions.

    Its vaccine portfolio includes Bexsero, a meningococcal B vaccine approved in 61 countries and incorporated into several national immunisation programmes across Europe. Since its launch in 2015, approximately 138 million doses of Bexsero have been distributed worldwide, making it one of the leading vaccines for the prevention of meningococcal B disease.

  • Emmerson secures procedural victory in Morocco arbitration over Khemisset potash project

    Emmerson secures procedural victory in Morocco arbitration over Khemisset potash project

    Emmerson PLC (LSE:EML) has achieved an important procedural milestone in its arbitration proceedings against the Kingdom of Morocco after the tribunal rejected Morocco’s request to have jurisdictional objections considered separately from the main case. Instead, the tribunal will hear the jurisdictional issues alongside the substantive claims, a decision that could simplify the arbitration process, although the timetable for the remaining stages has yet to be confirmed.

    The arbitration relates to claims brought under the bilateral investment treaty between the United Kingdom and Morocco. Through its subsidiaries, Emmerson is seeking US$1.215 billion in compensation, alleging the expropriation of its Khemisset Potash Project together with breaches of fair and equitable treatment and investment protection obligations. While the final outcome remains uncertain, the tribunal’s decision represents a significant procedural step that could influence the pace and direction of the case as the company seeks compensation for its investment in Morocco.

    Despite this legal development, Emmerson continues to face financial challenges, including the absence of revenue, widening losses, persistent negative free cash flow and a weakening equity position. Technical indicators are more encouraging, with the share price remaining above key longer-term moving averages and momentum showing signs of improvement. However, valuation remains constrained by ongoing losses and the lack of dividend support.

    More about Emmerson

    Emmerson PLC is an AIM-listed mining company focused on the development of potash resources through its subsidiaries, Khemisset UK Ltd. and Potasse de Khemisset S.A. Its principal asset is the Khemisset Potash Project in Morocco, which is intended to supply fertiliser markets with a strategically located source of potash.

    The company is pursuing the project while simultaneously seeking compensation through international arbitration over its investment in Morocco. Emmerson remains focused on creating long-term value from the Khemisset asset and strengthening its position within the global fertiliser and industrial minerals sector.

  • Insig AI launches digital asset investment strategy with stake in 4Mica

    Insig AI launches digital asset investment strategy with stake in 4Mica

    Insig AI (LSE:INSG) has taken its first step into the digital assets sector by committing an initial €300,000 through a zero-interest convertible loan to Belgium-based ATM Labs B.V., which trades as 4Mica. The investment is expected to complete within 45 days and marks the first transaction under Insig AI’s strategy of investing in businesses developing infrastructure for the digital asset economy.

    The convertible loan matures in August 2027 and, if converted, would provide Insig AI with a 2.94% fully diluted equity stake in 4Mica. The agreement also includes a conditional commitment of up to a further €1 million, subject to 4Mica completing a significant fundraising round within the next 16 months. The company is developing a non-custodial clearing platform for stablecoin-based AI micropayments, with technology designed to significantly reduce transaction costs while supporting substantially higher transaction volumes. Through the investment, Insig AI is seeking exposure to the growth of next-generation digital payment infrastructure.

    Despite expanding into a fast-growing market, Insig AI continues to face financial challenges, including ongoing losses, negative cash flow and negative shareholder equity. Technical indicators also remain weak, reflecting a longer-term downward share price trend. Valuation is difficult to assess given the company’s negative earnings and the absence of a dividend.

    More about Insig AI

    Insig AI plc is a UK-based technology company that develops artificial intelligence-driven data infrastructure and machine learning solutions for institutional clients. The business provides advanced analytics and technology platforms designed to support investment decision-making and data management.

    The company is increasingly focused on opportunities within the digital asset sector, targeting businesses that provide the underlying infrastructure for blockchain-based financial services rather than direct cryptocurrency exposure. By investing in early-stage technology companies with scalable platforms, Insig AI aims to give institutional investors access to emerging digital asset infrastructure and long-term growth opportunities.

  • Croma Security Solutions reports higher revenue and strengthens focus on high-margin security business

    Croma Security Solutions reports higher revenue and strengthens focus on high-margin security business

    Croma Security Solutions Group Plc (LSE:CSSG) expects to report fiscal 2026 revenue of approximately £11.0 million, representing growth of around 15% compared with the previous year and modestly exceeding market expectations. EBITDA is forecast to be around £1 million as the company continues investing in its operations while pursuing long-term expansion.

    The completion of the £6.5 million sale of its Vigilant Security business, together with receipt of the final deferred payment, has enabled Croma to concentrate on its higher-margin locksmith and electronic security systems operations. During the year, the company integrated six acquisitions, including TLS Security Systems and Southern Security Services, expanding its network to 17 security centres across the UK and strengthening its presence in key regional markets.

    The latest trading update highlights continued demand from retail, commercial, healthcare and leisure customers as organisations increase investment in security infrastructure to meet evolving regulatory requirements and improve the protection of people and assets. With no bank debt and net cash of £4.9 million at year end, Croma enters the new financial year in a strong financial position, supported by a healthy pipeline of acquisition opportunities and a strategy focused on consolidating the fragmented UK locksmith and electronic security market.

    While the company benefits from a robust balance sheet and supportive valuation metrics, its outlook is moderated by weaker technical indicators and inconsistent cash flow generation, including a recent period of negative free cash flow. Nevertheless, its acquisition-led growth strategy continues to provide opportunities for further expansion.

    More about Croma Security Solutions

    Croma Security Solutions Group Plc is a UK provider of locksmith services and electronic security systems serving retail, commercial, healthcare and leisure customers. The company operates a growing national network of modern security centres and specialises in acquiring established independent locksmith and security businesses to expand its market presence.

    Following the disposal of its manned guarding subsidiary, Vigilant Security, Croma has sharpened its focus on higher-margin security services. Its enlarged network of 17 security centres, combined with a debt-free balance sheet and strong cash position, provides the company with the financial flexibility to continue pursuing acquisitions and organic growth opportunities across the UK security sector.

  • Big Yellow reports resilient first quarter as self-storage expansion gathers pace

    Big Yellow reports resilient first quarter as self-storage expansion gathers pace

    Big Yellow Group (LSE:BYG) delivered steady first-quarter trading for the period ended 30 June 2026, reporting total revenue of £53.2 million, up 3% from a year earlier. Like-for-like store revenue increased by 2%, while occupancy across the company’s 113-store portfolio grew by 161,000 square feet, lifting like-for-like closing occupancy to 79.2%. Average achieved net rent per square foot also rose 3%, reflecting continued pricing strength across the estate.

    The company is continuing to improve operational efficiency through investment in automation, solar energy and other energy-saving initiatives, alongside more targeted marketing aimed at managing rising operating costs, including higher business rates. Big Yellow is also expanding its UK footprint with a development pipeline of 12 new stores, supported by the recent acquisition of a site in Acton. Part of this expansion is being funded through the £38.4 million disposal of its Harrow industrial estate. Once completed, the development pipeline is expected to generate around £35 million in additional net operating income and further strengthen the company’s position in the UK self-storage market.

    Big Yellow continues to benefit from a solid financial profile, supported by revenue growth, conservative leverage and an attractive dividend yield. However, these strengths are offset by weaker technical indicators, negative share price momentum and more inconsistent cash generation, including a recent decline in free cash flow.

    More about Big Yellow Group

    Big Yellow Group PLC is the UK’s largest self-storage operator, with a network of 113 stores offering a maximum lettable area of approximately 6.7 million square feet. The majority of its properties are owned on a freehold or long leasehold basis, with around three-quarters of revenue generated from London and the surrounding commuter belt, alongside major regional cities across the UK.

    The company focuses on highly visible and accessible locations, supported by advanced digital systems for customer service, security and operational management. Alongside its expansion programme, Big Yellow continues to invest in sustainability initiatives and expects its pipeline of 12 additional stores to increase total capacity to around 7.6 million square feet.

  • Prologis increases offer for SEGRO with revised share and cash proposal

    Prologis increases offer for SEGRO with revised share and cash proposal

    Prologis (NYSE:PLD) has submitted a third revised proposal to acquire SEGRO (LSE:SGRO), valuing the UK logistics property company at approximately £13.5 billion. The latest proposal consists of 0.0890 newly issued Prologis shares for each SEGRO share, alongside a partial cash alternative of up to £2.7 billion at 1,000 pence per share. SEGRO’s board has rejected the proposal once again. If the transaction were completed, existing SEGRO shareholders would own around 9.2% of the enlarged Prologis group. The offer represents a premium of about 10% to SEGRO’s adjusted net asset value and more than 30% above the company’s share price before the approach became public.

    Prologis believes its revised proposal delivers greater immediate value and flexibility than SEGRO’s standalone strategy, arguing that the company’s long-term plans depend on ambitious property valuations and the successful execution of an extended development pipeline. The U.S.-based real estate group also highlighted its strong second-quarter performance and continued expansion in its data centre and power infrastructure businesses as evidence of its growth prospects. Prologis is encouraging SEGRO shareholders to urge the board to enter discussions regarding a potential transaction, while also considering a secondary listing in London. However, the company reiterated that there is no certainty a formal takeover offer will ultimately be made.

    More about Prologis

    Prologis, Inc. is one of the world’s largest industrial real estate companies, specialising in logistics facilities and warehouse properties across major global markets. In recent years, the business has expanded into digital infrastructure, building a growing portfolio of data centres and power-related assets to support increasing demand from technology and logistics customers.

    The company combines a large-scale property development platform with long-term asset management, focusing on generating sustainable rental growth, expanding funds from operations and delivering value for shareholders through its global logistics real estate portfolio.